Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bupropion.

Scott Wilkes1

  • 1Centre for Primary and Community Care, School of Health, Natural & Social Sciences, University of Sunderland, Sunderland, UK. scott.wilkes@sunderland.ac.uk

Drugs of Today (Barcelona, Spain : 1998)
|December 1, 2006
PubMed
Summary
This summary is machine-generated.

Bupropion, a medication for depression and smoking cessation, also shows anti-inflammatory effects and helps with ADHD symptoms. Despite its effectiveness, its use for smoking cessation is less common than nicotine replacement therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes in NSTEMI Patients Based on Coronary TIMI Flow State on Presentation.

Journal of clinical medicine·2026
Same author

Left Main Stem Perforation: Management Strategies in a Potentially Catastrophic Event.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing UK Population with Subclinical Hypothyroidism: Emulated Target Trial (ACEL-UK-ETT).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Building capacity in the academic general practice research workforce.

The British journal of general practice : the journal of the Royal College of General Practitioners·2025
Same author

Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study.

The Journal of clinical endocrinology and metabolism·2025
Same author

Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis.

Systematic reviews·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Bupropion approved for depression (1989), smoking cessation (1997/2000), and seasonal affective disorder (2006).
  • Primary mechanism involves dopamine and noradrenaline reuptake inhibition.
  • Demonstrates efficacy beyond its primary indications, including ADHD symptom management.

Purpose of the Study:

  • To review the multifaceted clinical applications and emerging properties of bupropion.
  • To highlight its efficacy in smoking cessation and potential anti-inflammatory actions.
  • To discuss its tolerability, drug interactions, and market penetration for smoking cessation.

Main Methods:

  • Literature review of bupropion's clinical trials and pharmacological studies.
  • Analysis of efficacy data for depression, smoking cessation, SAD, and ADHD.

Related Experiment Videos

  • Examination of safety profiles, drug interactions, and comparative uptake with nicotine replacement therapy.

    • Main Results:

    • Bupropion shows sustained smoking abstinence rates of approximately 20% at one year across diverse patient groups.
    • Emerging evidence suggests anti-inflammatory action against tumor necrosis factor-alpha (TNF-alpha).
    • Well-tolerated, with common side effects including insomnia and dry mouth; potential for drug interactions exists.

    Conclusions:

    • Bupropion is a versatile medication with established efficacy for depression, SAD, and smoking cessation, plus emerging roles in ADHD and inflammation.
    • Its anti-inflammatory properties warrant further investigation for conditions like Crohn's disease.
    • Despite proven effectiveness and cost-effectiveness for smoking cessation, its utilization lags behind nicotine replacement therapy.